Oculis reported strong 2025 financial results and positive Phase 2 trial data for its eye disease drugs, with no new approvals.

Oculis reported its fourth-quarter and full-year 2025 financial results, highlighting continued progress in its ophthalmic drug development pipeline. The company noted advancements in clinical trials for its lead candidates, including positive interim data from a Phase 2 study. Oculis also updated its financial position, stating it remains well-capitalized to support ongoing research and development activities. No major regulatory decisions or product approvals were announced during the period.